Weight-loss drug stoppage and restart effects on brain, mood, and daily life
Official title: Clinical and Neurobehavioral Changes With GLP-1 (Glucagon-like Peptide-1) Discontinuation
Run by The University of Texas at Dallas · NCT07387796 · Data updated 2026-11-12
This study tests what happens to brain signals, mood, sleep, and daily functioning when a tirzepatide user pauses the medication and then restarts it.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | The University of Texas at Dallas Academic / other |
| Locations | 1 site (Dallas, Texas) |
| Status | Recruiting |
| Started | October 2026 |
| Main results expected | February 2028 |
| Study ends | February 2029 |
| Registry record updated | September 2, 2026 |
| Trial ID | NCT07387796 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18-70 currently prescribed tirzepatide and receiving care at the UT Southwestern Weight Wellness Clinic who are able to consent and complete English-language assessments.
✕Probably not a fit
Individuals not experiencing changes in brain responses or daily functioning during the stop/restart period, or those with contraindications or intolerances to study procedures, may see no direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults aged 18-70 who are currently taking tirzepatide will undergo three in-person visits to measure changes in brain responses to food cues, behavior, and health outcomes as tirzepatide is stopped for 3-4 weeks and then restarted for 6-8 weeks. The study uses a within-subject design without a separate control group, focusing on changes across three time points: on tirzepatide, after discontinuation, and after reinitiation. Participants will complete interviews, questionnaires, and cognitive tasks and may undergo neuroimaging and other assessments as part of standard clinical care. All procedures are conducted in the context of routine prescribing and are not altering the patient’s medical treatment beyond the study timeline.
Why it matters
Potential benefit: If successful, the study could clarify how stopping and restarting tirzepatide impacts hunger, mood, and quality of life, informing safer use and management for patients.
How similar studies have gone: Prior work with similar within-subject approaches has shown potential to reveal brain and behavioral changes related to weight-management medications, though this exact stoppage/restart design is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18-70 years. * Currently on tirzepatide. * Currently receiving care from University of Texas- Southwestern (UTSW) Weight Wellness Clinic. * Cognitively capable of understanding and signing informed consent. * Be proficient in English. Exclusion Criteria: * History of major neurological or psychiatric disorders, including substance use disorders that might confound brain imaging results (e.g., stroke, epilepsy, multiple sclerosis, schizophrenia, major depression requiring hospitalization). * Diagnosis of Type 2 Diabetes. * Current diagnosis of an eating disorder. * Use of medications affecting weight other than tirzepatide. * Pregnancy or breastfeeding. * MR contraindications: * Heart pacemaker, heart valve replacement, or aortic clips * Metal fragments in the eyes, skin, or elsewhere in the body * Brain clips or pieces of metal used in aneurysm surgery or intercranial bypass * Venous umbrella * Pieces of metal in the body resulting from work as a sheet-metal worker or welder * Clips placed in an internal organ * Prosthetic devices, such as middle ear, eye, joint, or penile implants * Joint replacement * Hearing aid that cannot be removed * Neurostimulator * Insulin pump * Shunts or stents * Metal mesh or coil implants * Metal plate, pin, screws, or wires, or any other metal implants
Where it's running
-
Center for BrainHealth
Dallas, Texas, United States Recruiting
Study contacts
- Principal investigator: Francesca Filbey, Doctor of Philosophy — The University of Texas at Dallas
- Study coordinator: Samuel H Poelker-Wells, Master of Science
- Email: sxp230129@utdallas.edu
- Phone: 972-883-3375
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Interprofessional Training to Improve Care for Peri-Delivery Patients with Substance Use Disorder
This program tests INSPIRE, a set of online and in-person trainings for healthcare teams to reduce stigma and improve care for people with substance use disorder around labor, delivery, and postpartum at the University of Utah.
-
Effects of comorbidity on people with severe mental illness
This study tests how having both alcohol/substance use and a severe mental illness affects hospitalizations, medications, and social participation among adults followed at a mental health center.
-
Interdisciplinary support to smooth care transitions for hospitalized adults with substance use disorders
This study tests a team-based in-hospital and post-discharge program to help adults with substance use disorders move from hospital care to ongoing community treatment.
-
Maintaining Independence and Sobriety through Systems Integration, Outreach, and Networking-Criminal Justice (MISSION-CJ) for re-entry
This trial tests a multicomponent program called MISSION-CJ with Peer Linkage Support to help adults released from two Massachusetts jails who have both mental health and substance use disorders.
-
Helping toddlers of caregivers with substance use disorders build language skills with group and individualized parenting supports
This project will test whether adding coaching and one-on-one lessons to a group parenting program helps toddlers (12–42 months) of caregivers with substance use disorders develop better language skills.
-
Recovery Inspired Support Engagement: A 12‑week 1-on-1 program for families and friends supporting someone in recovery
A 12‑week telehealth program will test whether a one‑on‑one support program for people who support loved ones in substance use recovery is doable and acceptable.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.